Tumor expression of Fas ligand (CD95L) and the consequences.
Tumors of diverse origin have recently been shown to express CD95 ligand and to induce apoptosis in CD95-expressing targets in vitro; however, in vivo, enhanced tumor growth and rejection have both been observed as a consequence of either immunosuppressive or proinflammatory functions of CD95 ligand. The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment.
Walker
P R
PR
Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 rue Micheli-du-Crest, CH-1211, Geneva 14, Switzerland. Paul.Walker@hcuge.ch
Saas
P
P
Dietrich
P Y
PY
D000818:Animals; D053222:Fas Ligand Protein; D006801:Humans; D008562:Membrane Glycoproteins / Q000032:analysis / Q000502:physiology*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins